key: cord-0997425-9e7g5bye
authors: Morillas, Jose A.; Marco Canosa, Francisco; Srinivas, Pavithra; Asadi, Tannaz; Calabrese, Casandra; Rajendram, Prabalini; Budev, Marie; Poggio, Emilio D.; Narayanan Menon, KV; Gastman, Brian; Koval, Christine
title: Tocilizumab therapy in five solid and composite tissue transplant recipients with early ARDS due to SARS‐CoV‐2
date: 2020-05-31
journal: Am J Transplant
DOI: 10.1111/ajt.16080
sha: 9b5e9dd21ddd37656dc1b99a97cf06c8bd72274d
doc_id: 997425
cord_uid: 9e7g5bye

There is emerging data depicting the clinical presentation of COVID‐19 in solid organ transplant recipients but negligible data‐driven guidance on clinical management. A biphasic course has been described in some infected with SARS‐CoV‐2, beginning with a flu‐like illness followed by an intense inflammatory response characterized by elevated c‐reactive protein (CRP), interleukin 6 (IL‐6), and acute respiratory distress syndrome (ARDS) associated with high mortality. The exuberant and possibly dysregulated immune response has prompted interest in therapeutic agents that target the cytokines involved, particularly IL‐6. Tocilizumab is an IL‐6 receptor antagonist with a record of use for a variety of rheumatologic conditions and cytokine release syndrome due to CAR T‐cell therapy but experience in solid organ and composite tissue transplant recipients (SOT/CTTRs) with SARS‐CoV‐2‐related ARDS has not been previously reported in detail. We present the clinical course of five SOT/CTTRs with SARS‐CoV‐2‐related ARDS that received tocilizumab with favorable short‐term outcomes in four. Responses were characterized by reductions in CRP, discontinuation of vasopressors, improved oxygenation and respiratory mechanics, and variable duration of ventilator support. Four bacterial infections occurred within two weeks of tocilizumab administration. We discuss safety concerns and the need for randomized comparative trials to delineate tocilizumab’s clinical utility in this population.

The novel coronavirus (SARS-CoV-2), causal agent of coronavirus disease 2019 (COVID- 19) , was first reported in Wuhan, China in December 2019 1 and has rapidly spread to cause the worst pandemic since 1918. Over 4 million cases have been reported worldwide with mortality of 6.7% (coronavirus.jhu.edu). The poorest outcomes are described in those with comorbidities, including older age, diabetes, hypertension, renal failure, obesity, advanced heart and lung disease [2] [3] [4] [5] .

Solid organ and composite tissue transplant recipients (SOT/CTTRs) may be at greater risk for severe manifestations of SARS-CoV-2 as they are for other RNA respiratory viruses, including influenza and RSV. 6 Early data from Italy, in a cohort of pediatric transplant patients, indicated that liver transplant recipients did not develop severe pulmonary manifestations, suggesting that transplant-related immunocompromise in the absence of comorbidities is not a predictor of poorer outcomes 7 . However, more recent data indicate adult SOTRs are not protected from severe manifestations of COVID-19 8 . Some have posited that transplant immune suppression may dampen the harmful immune response, making it unclear how to manage immune suppression in the setting of

A biphasic disease course has been described in about a third of patients with COVID-19 beginning with a flu-like illness and transitioning 7-14 days later to a period of robust immunologic response characterized by acute respiratory distress syndrome (ARDS) and elevated markers of inflammation. [9] [10] [11] [12] [13] The critical illness and high mortality engendered in the inflammatory phase has sparked great interest in specific cytokines, particularly interleukin-6 (IL-6), as therapeutic targets 14 .

Tocilizumab is a human monoclonal IL-6 receptor antagonist that has been used successfully for treatment of rheumatoid arthritis, giant cell arteritis and cytokine release syndrome (CRS) due to CAR-T cell therapy 14, 15 . Potential side effects include liver injury and fungal, bacterial and mycobacterial infections. Tocilizumab has now been reported as therapy in short case series of patients with severe COVID-19 and demonstrates some promise in abrogating the immediate deleterious effects of the immune response 16 . With immunologic effects that may persist for weeks, it is unclear if tocilizumab will benefit SOT/CTTRs in the setting of existing immune suppression and if there will be unanticipated consequences.

This article is protected by copyright. All rights reserved

Here we present five SOT/CTTRs (Table 1) with SARS-CoV-2-related ARDS in which tocilizumab was used with favorable short-term outcomes in four. Figure 1 depicts the clinical courses of these five patients from symptom onset.

A 53 year-old female medical receptionist with hypertension, kyphoscoliosis, and five prior kidney transplants (latest, 5 years previously, with creatinine 1.4 mg/dL), maintained on mycophenolate mofetil (MMF), tacrolimus, and prednisone presented to the emergency room (ER) with cough, chest pain, fever, fatigue, diarrhea and shortness of breath (SOB) for four days. Her temperature was 37.9°C, blood pressure (BP) 93/63 mm/Hg, heart rate (HR) 85 beats per minute (bpm), respiratory rate (RR) 22 breath per minute (Bpm), and oxygen saturation (SpO2) of 92% on room air (RA).

Lungs were clear to auscultation. Laboratory data showed a white blood cell count (WBC) of 8.46 k/uL (normal: 3.7-11), absolute lymphocyte count (ALC) of 0.28 k/uL (normal: 1.0-4.0), hemoglobin (Hb) of 14.3 g/dL, platelets of 127 K/uL, creatinine 1.7 mg/dL, ALT 26 U/L, AST 25 U/L, lactate 1.2 mmol/L (normal 0.5-2.2). A chest x-ray (CXR) showed severe scoliosis and no pulmonary infiltrates.

A nasopharyngeal (NP) swab for influenza and respiratory syncytial virus (RSV) polymerase chain reaction (PCR) was negative. SARS-CoV-2 RT-PCR was positive.

MMF was discontinued and tacrolimus dose adjusted. The following day, she became hypotensive and more hypoxic. A CXR showed bilateral pulmonary patchy infiltrates. She was transferred to the intensive care unit (ICU) and treated with stress dose steroids, hydroxychloroquine, and lopinavir/ritonavir. Due to hypoxemia and respiratory distress, she required intubation and mechanical ventilation (day 7). Labs included ALC 0.22 k/uL, C-reactive protein (CRP) 9.7 mg/dL (ref <0.9 mg/dL), ferritin 535 ng/mL (14.7-205.1 ng/mL), procalcitonin 0.1 ng/mL (ref<0.09 ng/mL, etc), LDH 234 U/L (135-214), pro-BNP 3214 (ref<125), and troponin T<0.010 ng/mL. PaO2/FIO2 ratio was 196 (PEEP 12 cmH 2 O). Shortly after intubation, a blood sample for IL-6 concentration was collected and one dose of tocilizumab 400 mg intravenously was given. One day later, her CRP declined to 3.5 mg/dL and continued trending down over the next days. Vasopressors and stress-dose steroids were discontinued, and ventilator settings were lowered (FiO2 from 80% to 30%; PEEP from 12 to 5 cmH 2 0) over the next three days. On day 11 of illness, she developed fever and was found to

This article is protected by copyright. All rights reserved have ventilator-associated pneumonia due to multidrug-resistant Pseudomonas aeruginosa treated with ceftolozane/tazobactam for seven days. Pre-tocilizumab IL-6 level came back at 7 pg/mL (ref<=5). She was extubated 13 days after tocilizumab dose and transferred to a regular nursing floor where she was treated for moderately severe Clostridioides difficile colitis. Twenty three days from illness onset her SARS-CoV-2-PCR resulted as negative twice separated by 24 hours. She remained hypoxic with cough and was discharged home on supplemental oxygen at 3 L/minute.

A 78 year-old man with a history of pulmonary fibrosis with left single lung transplant (6 years previously) complicated by chronic lung allograft dysfunction requiring supplemental oxygen at 1L/minute on tacrolimus and prednisone, diabetes mellitus, heart failure, hypertension, end stage renal disease on hemodialysis and recent bladder cancer presented to the emergency department with dry cough and worsening dyspnea on exertion for three days. He was afebrile, BP 124/68 mm/Hg, HR of 99 bpm, RR of 32 Bpm, and SpO2 of 91% on supplemental oxygen at 4L/minute. He had bilateral crackles on lung auscultation. Laboratory data showed WBC 17.14 k/uL, ALC 3.12 k/uL, Hb 13.1 g/dL, platelets 145 K/uL, creatinine 3.34 mg/dL, ALT 20 U/L, AST 43 U/L, lactate 1.5 mmol/L. A CXR showed a consolidative infiltrate in the left transplanted lung and stable interstitial infiltrates in the right native lung. A NP swab for rapid influenza and RSV PCR resulted negative.

He received empiric vancomycin, piperacillin-tazobactam, and azithromycin, and was admitted to the ICU where he required intubation and mechanical ventilation (day 5). NP swab for SARS-CoV-2 RT-PCR returned positive. PaO2/FIO2 ratio 200 (PEEP 12 cmH2O). Laboratory findings included CRP 18.8 mg/dL, ferritin 610 ng/mL, procalcitonin 1.07 ng/mL, pro-BNP 49,000 and troponin T 0.366 ng/mL with an electrocardiogram revealing ventricular-paced rhythm. He received piperacillin-tazobactam for five days due to concerns for bacterial co-infection and hydroxychloroquine. A blood sample for IL-6 concentration was collected (later resulting at 13pg/mL) and tocilizumab 400 mg intravenously was given (day 5). His CRP declined to 12.9mg/dl one day later. He was extubated four days later and transferred to a regular nursing floor. CRP normalized after 11 days. Repeat CXR on day 17 showed improvement of left consolidation. He returned to his baseline use of supplemental oxygen (1 L/minute) at day 18. His discharge was

This article is protected by copyright. All rights reserved delayed due to persisting positive results of SARS-CoV-2 RT-PCR from NP swab at day 32 from symptoms onset.

A 51 year-old male residing at long term care facility with morbid obesity, hypertension, diabetes mellitus, granulomatosis with polyangiitis in remission, face transplantation (5 years previously) due to disfigurement from a motor vehicle accident on tacrolimus and prednisone, and chronic respiratory failure (secondary to P. aeruginosa pneumonia) on supplemental O2 via tracheostomy was transferred from outside hospital ICU after one week of respiratory symptoms, fever and worsening respiratory Hydroxychloroquine had been started at outside hospital and was continued. Stress-dose steroids and empiric antimicrobials (piperacillin-tazobactam and vancomycin) were started. Labs with procalcitonin 3.12 ng/mL, CRP 36.5 mg/dL. Due to acute worsening of ventilator requirements, a blood sample for IL-6 concentration was collected (later resulting at 438 pg/mL) and one dose of tocilizumab 400 mg intravenously (day 10) was given. One day after tocilizumab, vasopressors were stopped, ventilator settings decreased and CRP declined to 21.2 mg/dL. Pseudomonas aeruginosa was identified as susceptible and monotherapy with piperacillin-tazobactam was continued. CRP downtrended, however he had worsening leukocytosis, hypotension, and increased respiratory secretions with worse oxygen requirement. New tracheal aspirate culture grew XDR P. aeruginosa and started on ceftolozane-tazobactam for right sided pneumonia. Due to persisting signs of infection, a bronchoalveolar lavage was performed and grew abundant Corynebacterium striatum and XDR P.

aeruginosa. With combination therapy (ceftolazane-tazobactam, inhaled colistin, vancomycin) he

improved and requiring minimal ventilatory support. He was discharged on day 24 of admission to his long term care facility where he continues to recover.

A 69 year-old woman with hepatitis C liver cirrhosis resulting in liver transplant (3 years previously) on cyclosporine, rheumatic heart disease, and chronic kidney disease stage 3 presented to the ER with fevers, fatigue, myalgias, sore throat, diarrhea and progressive dyspnea for 6 days. Her temperature was 38.7°C, BP 124/48 mm/Hg, HR 56 bpm, RR 13 Bpm, and SpO2 98% on RA. Left sided rales in mid lung field were present. Laboratory data showed WBC of 1.53 k/uL, ALC 0.47 k/uL, Hb 9.2 g/dL, platelets 76 K/uL, creatinine 1.64 mg/dL, ALT 16 U/L, AST 30 U/L. A CXR showed a left perihilar infiltrate. A NP swab for rapid influenza and RSV PCR resulted negative. Empiric ceftriaxone and azithromycin were started, SARS-CoV-2 RT-PCR from NP swab was positive.

Antibiotics were discontinued. Over the next few days she developed fever, mild respiratory distress, and hypoxemia. CXR showed progressive extensive bilateral opacities. Hydroxychloroquine and supplemental oxygen via nasal cannula were started, and she was transferred to the ICU. Labs included ALC 0.31 k/uL, CRP 5.2 mg/dL, and ferritin 561 ng/mL. After a few hours, she required intubation and mechanical ventilation (day 13). PaO2/FIO2 ratio was 283 (PEEP 14cmH2O).

Tocilizumab 310 mg (adjusted based on weight) intravenously was given, however baseline IL-6 level was not measured. Despite initial rapid decline in CRP, she developed new fevers and hypotension requiring vasopressors and stress-dose steroids. Repeated work up showed WBC 11.33 k/uL, CRP 5.3, procalcitonin 0.39. CXR showed worsening consolidative opacities. Due to concern for superimposed bacterial infection, she was treated empirically with vancomycin and piperacillintazobactam. Fevers resolved after 2 days of antibiotics. Over the next few days, vasopressor requirements decreased, stress-dose hydrocortisone discontinued, ventilator settings were lowered and CRP normalized. Blood and respiratory cultures were negative for infection. Unfortunately, she failed extubation in the setting of persistent delirium, atrial fibrillation with rapid ventricular response, worsening pulmonary edema, and hemoptysis in the setting of anticoagulation. She was transitioned to comfort measures and died 2 days later.

This article is protected by copyright. All rights reserved

A 57 year-old woman with history of hypertension, diabetes mellitus, pulmonary embolism, coronary artery by-pass graft surgery, and kidney transplantation (6 years previously) on azathioprine, tacrolimus, and prednisone presented to the ER with fatigue, sore throat, fevers, cough and diarrhea for four days. Her temperature was 36.7°C, BP 134/106 mm/Hg, HR 80 bpm, RR 24 Bpm, and SpO2 91% on RA, with improvement on 2L/minute oxygen NC. Lungs were clear. Laboratory data showed WBC of 9.72 k/uL, ALC 0.39 k/uL, Hb 12.2 g/dL, platelets 103 K/uL, creatinine 2.31 mg/dL (from prior 1.75 mg/dL), ALT 11 U/L, AST 37 U/L. CXR showed linear densities in right lower lung. A NP swab for influenza/RSV PCR was negative. NP swab for SARS-CoV-2 RT-PCR returned positive.

Her labs were significant for a CRP 32.7 mg/dL and procalcitonin 2.30 ng/mL. Hydroxychloroquine was given and azathioprine was discontinued. Empiric ceftriaxone and azithromycin were added for possible bacterial infection, which were later changed to ertapenem for ESBL Escherichia coli in urine. She had worsening respiratory status (5-6 L/minute via NC) and bilateral opacities in CXR. She was transferred to the ICU and required mechanical ventilation (day 11). Labs included ALC 0.16 k/uL, CRP 17.9 mg/dL, ferritin 1176 ng/mL. PaO2/FiO2 ratio was 156 (PEEP of 14 cmH2O). She developed shock requiring vasopressors and stress-dose steroids; and acute renal failure with renal replacement therapy. Despite initial CRP decline (9.4mg/dL), tocilizumab 400 mg intravenously was given (day 12). One day post-dose the CRP declined to 6.6 mg/d, vasopressors and stress-dose steroids were discontinued, and 2 days post-dose she was extubated. CRP normalized 8 days later. She was transferred to regular nursing floor and discharged on room air to a rehabilitation facility.

Herein, we describe the first detailed case series of five SARS-CoV-2 positive SOTRs (two kidney, one liver, one lung, and a face recipient) with multiple comorbidities who were critically ill, required mechanical ventilation and were treated with a single dose of IL-6R antagonist tocilizumab early after intubation. Rapid improvements were observed in markers of inflammation and, while four of the five survived their severe illness, it is not clear how the drug affected specific facets of their clinical course.

This article is protected by copyright. All rights reserved In these patients, we observed the biphasic disease course previously reported for those developing severe COVID-19 with a mean time of 8.8 days from self-reported symptom onset to respiratory failure associated with markers of inflammation. This demonstrates that the SOT population is not protected from the inflammatory storm by their immunosuppressive drugs. In the absence of directive data, there is uncertainty as to the dose selection, timing and number of doses of tocilizumab for managing COVID-19-related inflammation. Some propose administration prior to ventilatory support and some propose later use once classic findings of CRS emerge 17 . Early reports from China and a recent case report of tocilizumab use in a kidney transplant recipient with COVID-19 suggested some benefit to earlier dosing 14, 16, 17 . With multidisciplinary input, our institution stewarded the limited tocilizumab supply by administering a single dose (capped at 400 mg) after intubation but prior to advanced multisystem organ involvement. Therefore, our patients uniformly received tocilizumab within 48 hours of mechanical ventilation, and all but one within 24 hours. Patient 3 had the most advanced signs of CRS (with very high CRP and IL-6 concentrations) at tocilizumab dosing with reversible renal failure requiring hemodialysis, though with concern for concomitant septicemia.

As expected, tocilizumab resulted in declining CRP (Figure 2 ) for all patients over 3-5 days 16 .

Lack of normalization appeared to be associated with bacterial superinfection in patient 3. We did not have IL-6 concentrations for all patients before tocilizumab due to the 4-7 day turn-around time making it less clinically directive. The pre-dose IL-6 concentrations available for three patients were widely different. While two patients had relatively low IL-6 levels, they fell within the range previously observed for patients with fatal outcomes 2 . Prior studies demonstrated that IL-6 can remain

This article is protected by copyright. All rights reserved stable for 2 weeks likely due to removal mechanisms (binding of receptors), and peaks on day 15-20 11 . For this reason, a surrogate of endogenous IL-6 production such as CRP may be more useful.

Additionally, tocilizumab blocks binding of IL-6, resulting in higher post-dose detectable levels in blood. Thus, pre-and post-dose IL-6 concentrations will be important in clinical trials of tocilizumab 18 .

The effects of tocilizumab on other outcomes in our patients is less certain. Four of five patients survived (80%) compared to 67% of those COVID-19 SOTRs requiring mechanical ventilation who did not receive tocilizumab in our regional hospital system. This may be better than in those historically reported in case series for critical COVID-19 and in 14 patients receiving tocilizumab within a recent broader series of SOTRs in New York City 8 , but our numbers are limited. In summary, we showed that tocilizumab can be used without major direct toxicity in SOT/CTTRs early after initiation of mechanical ventilation due to COVID-19, regardless of type of

This article is protected by copyright. All rights reserved organ transplanted. While it was temporally associated with the expected reductions in inflammatory markers and initial (but not always consistent) improvements in respiratory status, it is unclear whether it had any impact on major patient outcomes and if long term side effects will transpire.

While four of five patients survived, early nosocomial bacterial infections raise concerns for associated bacterial infection risk. Randomized clinical trials with comparative data are paramount to determine the true efficacy and risk of tocilizumab for use in patients, including SOT/CTTRs, with COVID-19.

The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.

The data that support the findings of this study are available from the corresponding author upon reasonable request. 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical predictors of mortality due to COVID-19 based on analysis of data of 150 patients from Wuhan, China

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Covid-19 in Critically Ill Patients in the Seattle Region -Case Series. NEJM

Influenza: A Recurrent Challenge to Transplantation

Coronaviruses and immunosuppressed patients. The facts during the third epidemic

COVID-19 in Solid Organ Transplant Recipients: Initial Report from the US Epicenter

COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal

COVID-19: consider cytokine storm syndromes and immunosuppression

Accepted Article This article is protected by copyright. All rights reserved

Immunopathological characteristics of coronavirus disease

Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients

The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

Effective Treatment of Severe COVID-19 Patients with Tocilizumab

Covid-19 pneumonia in a kidney transplant recipient successfully treated with Tocilizumab and Hydroxychloroquine

Why tocilizumab could be an effective treatment for severe COVID-19

Current challenges and opportunities in the management of antibody-mediated rejection in lung transplantation

Accepted Article